This is a routine deal-marketing filing with no new material information. The reverse merger with Avere is progressing on schedule. Monitor for the S-4 registration statement and shareholder vote timeline, which will be the next key catalysts. The $251M convertible note raise and $150M PIPE provide a strong cash runway through key Phase 2b readouts.
Price Chart
Executive Summary
NextCure filed a 425 communication on August 4, 2026, publishing an Avere Therapeutics corporate presentation to potential PIPE investors. The presentation details AVR-001, a once-weekly oral IL-23 receptor antagonist for psoriasis, showing Phase 1 data comparable to J&J's Icotyde (icotrokinra) with a convenience advantage. This is a routine deal-marketing filing that confirms the reverse merger with Avere is progressing, with no changes to deal terms or new material financial disclosures.
Key Financial Metrics
Key Facts
- Filing is a 425 communication publishing an Avere Therapeutics corporate presentation for the proposed reverse merger.
- AVR-001 is a once-weekly oral peptide IL-23RA targeting psoriasis, with potential expansion into IBD and PsA.
- Phase 1 MAD study data shows AVR-001 achieved similar PASI reductions and PASI 75 response rates as J&J's Icotyde (icotrokinra) at Week 4 and Week 8.
- Avere closed on $251 million of convertible notes and executed a worldwide license (ex-Greater China) for AVR-001 from Hansoh Pharma.
- Pre-closing financings are expected to fund the combined company through Phase 2b psoriasis and UC readouts and Phase 3 psoriasis initiation.
- No changes to the merger terms or deal structure from the original July 14, 2026 announcement.
- The presentation is promotional in nature, targeting potential PIPE investors, and contains forward-looking statements with standard risk disclosures.
Financial Impact
No new financial figures disclosed. The filing reiterates the $250M equity value for Avere and the $150M minimum PIPE, and notes $251M in convertible notes closed by Avere.
Risk Factors
- Reverse merger structure means existing NXTC shareholders retain only ~2.7% of the combined entity, resulting in massive dilution.
- AVR-001 is still in early clinical development (Phase 1), with no guarantee of success in larger Phase 2b/3 trials.
- IL-23 IP space is crowded with potential for infringement claims by third parties.
- Phase 1 data is from trials conducted in China and New Zealand, which may not be directly predictive of U.S. clinical outcomes.
- The presentation acknowledges a bridging strategy to Western markets may be required.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001104659-26-090069 |
| Document: 0001104659-26-090069-index-headers.html | 0001104659-26-090069 |
| Document: 0001104659-26-090069-index.html | 0001104659-26-090069 |
| Document: 0001104659-26-090069.txt | 0001104659-26-090069 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | SC 13G | $5.44 | awaiting T+60 | — | $5.72 (+5.06%) |
Sep 25, 2026 4w ago | 425 | $5.08 | awaiting T+60 | — | $5.72 (+12.50%) |
Sep 25, 2026 4w ago | 8-K | $5.08 | awaiting T+60 | — | $5.72 (+12.50%) |
Aug 10, 2026 11w ago | 425 | $6.73 | awaiting T+60 | — | $5.72 (+15.08%) |
Aug 4, 2026 12w ago | 425 | $5.78 | awaiting T+60 | — | $5.72 (−1.12%) |
Aug 3, 2026 12w ago | Insider Buy | $5.78 | awaiting T+60 | — | $5.72 (−1.12%) |
Jul 29, 2026 12w ago | Insider Buy | $5.03 $4.98 | ▼ −0.99% | ▼ −3.46% | $5.72 (+13.62%) |
Jul 14, 2026 15w ago | 425 / 8-K | $6.58 $6.56 | ▼ −0.30% | ▼ −3.68% | $5.72 (−13.15%) |
Jul 14, 2026 15w ago | 8-K | $6.58 $6.56 | ▲ +0.30% | ▲ +3.68% | $5.72 (+13.15%) |
Jun 1, 2026 21w ago | 8-K | $3.38 $5.91 | ▲ +74.85% | ▲ +73.62% | $5.72 (+69.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers